← All trials
NCT04484051
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2020
- Primary completion
- Jan 1, 2024
- Completion date
- Jan 1, 2024
- First posted
- Jul 23, 2020
- Last posted
- Jul 23, 2020
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Erasmus University RotterdamLead sponsor
- PfizerCollaborator
- Erasmus University RotterdamOverall official - principal investigator
- Erasmus University RotterdamReponsible party - principal investigator
- Foundation for Prader-Willi ResearchCollaborator
- Prader-Willi FondsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.